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Staphylococcus aureus, like other bacterial pathogens, scavenges host iron for growth through incompletely
understood mechanisms. In this issue of Cell Host & Microbe, Spaan et al. (2015) demonstrate that two
Staphylococcus aureus leukotoxins, HlgAB and LukED, target the Duffy antigen receptor for chemokines
on erythrocytes, resulting in lysis and iron release.A bacterial pathogen entering a mamma-
lian host is placing a substantial bet on
its ability to withstand iron starvation. Mi-
crobial access to iron, which is essential
for growth, is limited by sequestration
within host cells, limited solubility of free
iron at neutral pH, and binding by host
molecules. Effective bacterial pathogens
have developed multipronged appro-
aches to liberate iron from the grip of
the host (Skaar, 2010). Such strategies
include production of small molecules
that bind free iron with exceptional affinity
(siderophores); binding and uptake of
iron-associated host factors such as lac-
toferrin, transferrin, and hemoglobin; and
liberation of iron from intracellular pools
using cytotoxins. The outcome of infec-
tion, both systemic and localized, may
hinge on the host’s ability to withstand
or to directly counteract (such as through
the production of siderophore-binding lip-
ocalins) bacterial attempts to gain access
to iron (Ganz and Nemeth, 2015).
Staphylococcus aureus is an efficient
colonizer and a particularly vexing human
pathogen that is responsible for an aston-
ishingworldwideburdenofdisease.Within
the host, S. aureus preferentially uses
hemoglobin as a source of iron (Pishchany
et al., 2014), but its specific means of
gaining access to that target have re-mained unclear. Given the diverse array
of pore-forming toxins (PFTs) produced
by S. aureus—including a-, b-, and g-he-
molysins; other bicomponent cytolysins
such as the Panton-Valentine leukocidin;
and the phenol-soluble modulins—as
well as the large reservoir of hemoglobin-
bound iron contained in circulating eryth-
rocytes, it has been hypothesized that
PFT-mediated hemolysis likely provides a
source of iron for S. aureus in vivo. How-
ever, to date, the question of which of
these PFTs target human erythrocytes
in vivo has not been resolved. A clear un-
derstanding has been confounded by the
fact that a-toxin efficiently lyses rabbit
but not human erythrocytes, and several
other S. aureus toxins are either inacti-
vatedbyserum factorsor selectively target
leukocytes rather than erythrocytes.
In this issue of Cell Host & Microbe,
Spaan et al. (2015) take a major step for-
ward in understanding the interplay
among S. aureus toxins, erythrocytes,
and pathogenesis by demonstrating that
two S. aureus bicomponent cytolysins,
HlgABandLukED,exploit theDuffyantigen
receptor for chemokines ([DARC]; also
called atypical chemokine receptor 1) as
a cellular receptor to mediate erythrocyte
lysis, thus releasing iron. DARC, a seven-
transmembrane protein expressed primar-ily on erythrocytes and endothelial cells,
has a history as an important factor in
human infectious diseases (Horuk, 2015).
As an essential receptor for invasion of
erythrocytes by Plasmodium vivax and
P. knowlesi, DARC has served as a model
to understand malaria pathogenesis and
parasite-host interactions. At the level of
human populations, there is strong evi-
dence for selection on specific DARC
allelic variants. A promoter polymorphism
that alters GATA-1 transcription factor
binding and selectively abolishes DARC
expression on erythrocytes has reached
fixation in human populations in sub-Sa-
haran Africa and is thought to be a major
factor in the absence of P. vivax disease
from that region. Other variants, including
the FY*B allele used by Spaan et al.
(2015), decrease but do not eliminate cell
surface DARC.
DARCalsoactsasapromiscuousdecoy
(non-signaling) chemokine receptor on
erythrocytes and endothelial cells. It dir-
ectly binds several chemokine ligands
and can buffer serum concentrations of
such proteins by sequestering them from
traditional, signal-transducing receptors
(Dawson et al., 2000). This ‘‘chemokine
sink’’ effect prevents rapid, high-amplitude
changes in chemokine concentrations,
alters local and systemic immunity, and
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Figure 1. DARC-Dependent Toxins Liberate Host Hemoglobin and Prime Staphylococcus aureus Growth
Top panel, left to right: An erythrocyte with cell surface DARC (DARC+) is bound by a S. aureus HlgAB or LukED toxin monomer (green rectangle representing the
S subunit of a bicomponent cytolysin). A toxin heterodimer (green and yellow rectangles) forms, followed by hetero-oligomerization (not shown) and pore forma-
tion. This sequence of events leads to erythrocyte lysis and release of free hemoglobin (multicolor structure), the primary iron source for S. aureus (blue circles)
within the host.
Bottom panel: An erythrocyte lacking DARC (DARC) is not bound by the toxin S subunit, blocking initiation of the process.
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bacterial pneumonia (Mei et al., 2010). In
addition, endothelial DARC can modulate
local chemokine availability by mediating
transport of its ligands transport between
abluminal and luminal compartments
(Pruenster et al., 2009). DARC forms
homo-oligomers, but it may also antago-
nize the activity of signaling receptors
through the generation of non-functional
hetero-oligomers. Thus, DARC is deeply
entwined with baseline immune function
as well as the outcome of specific
infections.
The studies presented in Spaan et al.
(2015) continue the recent renaissance in
identification of host cell receptors for
S. aureus toxins and also provide a poten-
tial answer to the riddle of how S. aureus
liberates iron from erythrocytes in vivo.
The investigators observed that cells
from certain donors were resistant to
HlgAB and LukED, the S. aureus PFTs
with greatest lytic activity against human
erythrocytes. Using blood from donors
with known genotypes corresponding
to different numbers of cell surface ery-
throcyte DARC molecules, assessment
of toxin-receptor interactions by surface
plasmon resonance, and transfection ex-periments, the investigators determined
thatDARCexpressionwasbothnecessary
andsufficient forHlgAB-andLukED-medi-
ated hemolysis. Mutagenesis and compe-
tition studies demonstrated that each of
these toxins targets a distinct area of
DARC. When whole S. aureus was grown
in the presence of human erythrocytes,
the PFT-DARC interaction was required
for hemolysis and iron-mediated priming
of S. aureus growth. Likewise, in a murine
infection model, deletion of DARC-target-
ing PFTs attenuated within-host growth
considerably. Taken together, these
studies provide strong evidence that
S. aureus toxins target DARC as a means
to liberate hemoglobin from erythrocytes,
enhancing bacterial growth (Figure 1).
Elucidation of the HlgAB/LukED-DARC
interaction reveals a number of important
paths for future studies. PFT-induced he-
molysis has generally been thought to be
the result of rapid osmotic lysis. However,
there is a growing appreciation for the
importance of programmed cell death
pathways as contributors to toxin-induced
cytolysis, even in anucleate erythrocytes.
Some human-specific PFTs drive erythro-
cyte necroptosis, increasing the efficiency
of lysis and subsequent bacterial growthCell Host & Microbe 18, S(LaRocca et al., 2014). Given DARC’s role
as a cell surface receptor that may cluster
in the presence of oligomer-forming li-
gands such as PFTs, investigation of
potential downstream signaling events
that may intersect with known or novel
programmed cell death pathways is
warranted.
There may be implications for these
receptor/ligand interactions beyond iron
acquisition through erythrocyte lysis.
HlgAB and/or LukED might target endo-
thelial DARC as well, and lysis of such
cells could promote tissue invasion,
liberate other nutrient sources, or expose
microenvironments conducive to attach-
ment and growth. Disruption of DARC-
mediated endothelial chemokine trans-
port as a result of PFT binding could alter
local responses and facilitate bacterial
survival, or DARC could directly mediate
transport of toxin monomers or oligomers
across endothelial barriers.
DARC/ mice are viable (Dawson
et al., 2000) and may prove useful in
future experiments to further elucidate
the role of the DARC-PFT interaction
in vivo. In addition, the development of a
conditional DARC allele could untangle
cell-type-specific effects during infection.eptember 9, 2015 ª2015 Elsevier Inc. 273
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remain about exactly how HlgAB and
LukED interact with DARC. From the cur-
rent set of experiments, it appears that
HlgAB and LukED likely bind to different
regions of DARC, but the specific charac-
teristics of the binding interface—
including both host and toxin residues
involved—and the in vivo effects of such
binding on the function of erythrocyte
DARC as a chemokine sink remain to be
determined.
Finally, it is intriguing to speculate about
a potential role of human variation inDARC
expression as a driver of risk for S. aureus
infections. Neither of the two large ge-
nome-wide association studies examining
the relationship betweenS. aureusdisease
and host genetics performed to date have
identified DARC variation as a significant
driver of risk (Shukla et al., 2015), although274 Cell Host & Microbe 18, September 9, 20relative homogeneity of the study popula-
tions may be relevant to their power to
detect such associations. Targeted inves-
tigations of study populations with known
DARC polymorphisms may help address
these questions more directly. Likewise,
interference with the PFT-DARC interac-
tion may be a promising strategy for pa-
tients with S. aureus infections, especially
those with prolonged bacteremia.
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